4- ((1- (2- (2- (2- (6- amidino- 1- ethylindol- 2- yl)ethyl)pyrrolidinyl)- 2- oxoethyl)- 2- oxoazaperhydroepin- 3- yl)amino)butanoic acid (AT 1459)
AT-1459 is the (2S,3S)-isomer; structure in first source
Also Known As:
AT 1459; AT-1459; AT1459
Networked: 1
relevant articles (1 outcomes,
1 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
Related Diseases
1. | Venous Thrombosis (Deep-Vein Thrombosis)
12/01/2001
- " The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor (Ki = 4.9 nM) was evaluated in rat models of venous thrombosis combined with a bleeding time test and arterial thrombosis. " 12/01/2001
- " After drugs were given by i. v. bolus injection plus a continuous infusion, the ID50, (a dose that exhibits 50% inhibition of thrombus formation over each vehicle group) values of AT-1459, argatroban, and dalteparin were 0.04 mg/kg plus 0.04 mg/kg/h, 0.1 mg/kg plus 0.4 mg/ kg/h, and 13.0 IU/kg plus 26.0 IU/kg/h, respectively, in the venous thrombosis study. "
|
2. | Thrombosis (Thrombus)
12/01/2001
- " The oral antithrombotic effect of AT-1459 lasted for 6 after administering 30 mg/kg and improved the vessel patency significantly 1 h after administering the same dose in venous and arterial thrombosis models, respectively, with a rapid onset of action. " 12/01/2001
- " The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis." 12/01/2001
- " These results suggest that AT-1459 may be clinically useful as an orally available antithrombotic agent for the prevention of venous and arterial thrombosis." 12/01/2001
- " The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor (Ki = 4.9 nM) was evaluated in rat models of venous thrombosis combined with a bleeding time test and arterial thrombosis. " 12/01/2001
- " In a rat model of arterial thrombosis induced by topical FeCl2 application, intravenous administration of AT-1459, argatroban, and dalteparin improved the vessel patency significantly (P < 0.01) at 0.6 mg/kg plus 0.6 mg/kg/h, 0.6 mg/kg plus 2.4 mg/kg/h, and 300 IU/kg plus 600 IU/kg/h, respectively. "
|
|
Related Drugs and Biologics
Related Therapies and Procedures